Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Do you rebiopsy grade 1-2 follicular lymphoma if SUV is high by PET?
What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?
Related Questions
For patients with relapsed/refractory follicular lymphoma receiving mosunetuzumab, when, if ever, would you consider transitioning from intravenous to subcutaneous administration?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?
What is your approach to treatment of mantle cell lymphoma in someone with a mutated gene downstream of the BTK receptor, such as mutated CARD11?
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How do you approach patient with CLL/SLL limited to the prostate?
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?